'''Bazinaprine''' ('''SR-95,191''') is an experimental drug candidate. It is a [[monoamine oxidase inhibitor]] (MAOI) which is believed to be useful for the treatment of [[depression (mood)|depression]]. The drug strongly inhibits type A [[monoamine oxidase]], but only weakly inhibits type B. The effects of the drug are reversible [[in vivo]], but not [[in vitro]].<ref name=88newderivative>{{cite journal |pmid=3346672 |year=1988 |last1=Kan |first1=JP |last2=Steinberg |first2=R |last3=Leclercq |first3=J |last4=Worms |first4=P |last5=Biziere |first5=K |title=Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: Evidence for selective and reversible inhibition of monoamine oxidase type a in vivo but not in vitro |volume=50 |issue=4 |pages=1137–44 |journal=Journal of Neurochemistry |doi=10.1111/j.1471-4159.1988.tb10584.x}}</ref>  In studies, the chemical has been shown to not interact ''in vivo'' with other neurotransmitter or drug receptor sites.<ref name=87MAOI>{{cite journal |pmid=3100771 |year=1987 |last1=Kan |first1=JP |last2=Steinberg |first2=R |last3=Mouget-Goniot |first3=C |last4=Worms |first4=P |last5=Bizière |first5=K |title=SR 95191, a selective inhibitor of type a monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition |volume=240 |issue=1 |pages=251–8 |journal=The Journal of Pharmacology and Experimental Therapeutics |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3100771}}</ref> 
